REGULATORY

Japan Panel OKs Risk Management Measures for Potential Revlimid Generics

May 25, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

With multiple generic makers moving to develop their versions of Revlimid (lenalidomide), a blood cancer drug known to be teratogenic, a Japanese health ministry panel on May 24 approved specific risk management measures that should be followed by these companies…

To read the full story

Japan to Revise Revlimid Risk Management Rule in June; February Generic Approval Eyed
January 25, 2023
MHLW Panel Roughly OKs Scheme for Generic Makers to Join Revlimid Risk Management Program
June 23, 2021

REGULATORY

Japan Launches Biotechnology Working Group, Roadmap Draft Due in April
February 4, 2026
Japan Panel Backs Nonprescription Switch of Second Emergency Contraceptive
February 4, 2026
MHLW Set to Launch Searchable Drug Supply Database in April
February 3, 2026
MHLW Pushes Back GCP Ordinance Revision to Summer
February 3, 2026
Public Comments Warn Japan’s Drug Pricing System Cannot Reflect Inflation: Chuikyo
February 2, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

TSE’s Growth Market Reform Puts Pressure on Biotechs

By Tatsuya Otsuka

Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…